Literature DB >> 25111166

Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function.

Angel C Y Mak1, Clive R Pullinger1, Ling Fung Tang1, Jinny S Wong2, Rahul C Deo1, Jean-Marc Schwarz3, Alejandro Gugliucci3, Irina Movsesyan1, Brian Y Ishida4, Catherine Chu1, Annie Poon1, Phillip Kim5, Eveline O Stock1, Ernst J Schaefer4, Bela F Asztalos4, Joseph M Castellano6, Tony Wyss-Coray7, Jacque L Duncan8, Bruce L Miller9, John P Kane1, Pui-Yan Kwok1, Mary J Malloy1.   

Abstract

IMPORTANCE: The identification of a patient with a rare form of severe dysbetalipoproteinemia allowed the study of the consequences of total absence of apolipoprotein E (apoE).
OBJECTIVES: To discover the molecular basis of this rare disorder and to determine the effects of complete absence of apoE on neurocognitive and visual function and on lipoprotein metabolism. DESIGN, SETTING, AND PARTICIPANTS: Whole-exome sequencing was performed on the patient's DNA. He underwent detailed neurological and visual function testing and lipoprotein analysis. Lipoprotein analysis was also performed in the Cardiovascular Research Institute, University of California, San Francisco, on blood samples from the proband's mother, wife, 2 daughters, and normolipidemic control participants. MAIN OUTCOME MEASURES: Whole-exome sequencing, lipoprotein analysis, and neurocognitive function.
RESULTS: The patient was homozygous for an ablative APOE frameshift mutation (c.291del, p.E97fs). No other mutations likely to contribute to the phenotype were discovered, with the possible exception of two, in ABCC2 (p.I670T) and LIPC (p.G137R). Despite complete absence of apoE, he had normal vision, exhibited normal cognitive, neurological, and retinal function, had normal findings on brain magnetic resonance imaging, and had normal cerebrospinal fluid levels of β-amyloid and tau proteins. He had no significant symptoms of cardiovascular disease except a suggestion of myocardial ischemia on treadmill testing and mild atherosclerosis noted on carotid ultrasonography. He had exceptionally high cholesterol content (760 mg/dL; to convert to millimoles per liter, multiply by 0.0259) and a high cholesterol to triglycerides ratio (1.52) in very low-density lipoproteins with elevated levels of small-diameter high-density lipoproteins, including high levels of prebeta-1 high-density lipoprotein. Intermediate-density lipoproteins, low-density lipoproteins, and very low-density lipoproteins contained elevated apoA-I and apoA-IV levels. The patient's apoC-III and apoC-IV levels were decreased in very low-density lipoproteins. Electron microscopy revealed large lamellar particles having electron-opaque cores attached to electron-lucent zones in intermediate-density and low-density lipoproteins. Low-density lipoprotein particle diameters were distributed bimodally. CONCLUSIONS AND RELEVANCE: Despite a profound effect on lipoprotein metabolism, detailed neurocognitive and retinal studies failed to demonstrate any defects. This suggests that functions of apoE in the brain and eye are not essential or that redundant mechanisms exist whereby its role can be fulfilled. Targeted knockdown of apoE in the central nervous system might be a therapeutic modality in neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25111166      PMCID: PMC4714860          DOI: 10.1001/jamaneurol.2014.2011

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  39 in total

Review 1.  The liver sieve and atherosclerosis.

Authors:  Robin Fraser; Victoria C Cogger; Bruce Dobbs; Hamish Jamieson; Alessandra Warren; Sarah N Hilmer; David G Le Couteur
Journal:  Pathology       Date:  2012-04       Impact factor: 5.306

2.  Apolipoprotein E controls cerebrovascular integrity via cyclophilin A.

Authors:  Robert D Bell; Ethan A Winkler; Itender Singh; Abhay P Sagare; Rashid Deane; Zhenhua Wu; David M Holtzman; Christer Betsholtz; Annika Armulik; Jan Sallstrom; Bradford C Berk; Berislav V Zlokovic
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

3.  Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease.

Authors:  Lin T Guey; Clive R Pullinger; Brian Y Ishida; Patricia M O'Connor; Christian Zellner; Omar L Francone; Jason M Laramie; Josefina M Naya-Vigne; Ketevan A Siradze; Prakash Deedwania; Rita F Redberg; Philip H Frost; Albert B Seymour; John P Kane; Mary J Malloy
Journal:  Am J Cardiol       Date:  2011-08-01       Impact factor: 2.778

4.  Human apoC-IV: isolation, characterization, and immunochemical quantification in plasma and plasma lipoproteins.

Authors:  L Kotite; L-H Zhang; Z Yu; A L Burlingame; R J Havel
Journal:  J Lipid Res       Date:  2003-04-16       Impact factor: 5.922

5.  Regulated expression of apolipoprotein E by human retinal pigment epithelial cells.

Authors:  Brian Y Ishida; Kathy R Bailey; Keith G Duncan; Robert J Chalkley; A L Burlingame; John P Kane; Daniel M Schwartz
Journal:  J Lipid Res       Date:  2003-11-01       Impact factor: 5.922

6.  Unilamellar liposomes made with the French pressure cell: a simple preparative and semiquantitative technique.

Authors:  R L Hamilton; J Goerke; L S Guo; M C Williams; R J Havel
Journal:  J Lipid Res       Date:  1980-11       Impact factor: 5.922

7.  A method for quantitative scoring of the Farnsworth Panel D-15.

Authors:  K J Bowman
Journal:  Acta Ophthalmol (Copenh)       Date:  1982-12

8.  Type III hyperlipoproteinemia associated with apolipoprotein E deficiency.

Authors:  G Ghiselli; E J Schaefer; P Gascon; H B Breser
Journal:  Science       Date:  1981-12-11       Impact factor: 47.728

9.  The 1000 Genomes Project: data management and community access.

Authors:  Laura Clarke; Xiangqun Zheng-Bradley; Richard Smith; Eugene Kulesha; Chunlin Xiao; Iliana Toneva; Brendan Vaughan; Don Preuss; Rasko Leinonen; Martin Shumway; Stephen Sherry; Paul Flicek
Journal:  Nat Methods       Date:  2012-04-27       Impact factor: 28.547

10.  A framework for variation discovery and genotyping using next-generation DNA sequencing data.

Authors:  Mark A DePristo; Eric Banks; Ryan Poplin; Kiran V Garimella; Jared R Maguire; Christopher Hartl; Anthony A Philippakis; Guillermo del Angel; Manuel A Rivas; Matt Hanna; Aaron McKenna; Tim J Fennell; Andrew M Kernytsky; Andrey Y Sivachenko; Kristian Cibulskis; Stacey B Gabriel; David Altshuler; Mark J Daly
Journal:  Nat Genet       Date:  2011-04-10       Impact factor: 38.330

View more
  41 in total

1.  Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer's disease pathogenesis.

Authors:  Li Zhu; Minghao Zhong; Gregory A Elder; Mary Sano; David M Holtzman; Sam Gandy; Christopher Cardozo; Vahram Haroutunian; Nikolaos K Robakis; Dongming Cai
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-08       Impact factor: 11.205

Review 2.  Apolipoprotein E and Atherosclerosis.

Authors:  A D Marais
Journal:  Curr Atheroscler Rep       Date:  2021-05-10       Impact factor: 5.113

Review 3.  Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Authors:  Tien-Phat V Huynh; Albert A Davis; Jason D Ulrich; David M Holtzman
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

4.  Is apolipoprotein e required for cognitive function in humans?: implications for Alzheimer drug development.

Authors:  Courtney Lane-Donovan; Joachim Herz
Journal:  JAMA Neurol       Date:  2014-10       Impact factor: 18.302

5.  Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH.

Authors:  Hari Prasad; Rajini Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-26       Impact factor: 11.205

Review 6.  Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.

Authors:  Yu Yamazaki; Meghan M Painter; Guojun Bu; Takahisa Kanekiyo
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

Review 7.  Peripheral versus central nervous system APOE in Alzheimer's disease: Interplay across the blood-brain barrier.

Authors:  Dustin Chernick; Stephanie Ortiz-Valle; Angela Jeong; Wenhui Qu; Ling Li
Journal:  Neurosci Lett       Date:  2019-06-07       Impact factor: 3.046

Review 8.  A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

Authors:  Michaël E Belloy; Valerio Napolioni; Michael D Greicius
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

9.  ApoE knockout and knockin mice: the history of their contribution to the understanding of atherogenesis.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  J Lipid Res       Date:  2016-03-25       Impact factor: 5.922

Review 10.  The ApoE receptors Vldlr and Apoer2 in central nervous system function and disease.

Authors:  Courtney Lane-Donovan; Joachim Herz
Journal:  J Lipid Res       Date:  2017-03-14       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.